227 related articles for article (PubMed ID: 25130084)
1. A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide.
Kotsakis A; Papadimitraki E; Vetsika EK; Aggouraki D; Dermitzaki EK; Hatzidaki D; Kentepozidis N; Mavroudis D; Georgoulias V
Lung Cancer; 2014 Oct; 86(1):59-66. PubMed ID: 25130084
[TBL] [Abstract][Full Text] [Related]
2. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide.
Bolonaki I; Kotsakis A; Papadimitraki E; Aggouraki D; Konsolakis G; Vagia A; Christophylakis C; Nikoloudi I; Magganas E; Galanis A; Cordopatis P; Kosmatopoulos K; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Jul; 25(19):2727-34. PubMed ID: 17602077
[TBL] [Abstract][Full Text] [Related]
3. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
Brunsvig PF; Kyte JA; Kersten C; Sundstrøm S; Møller M; Nyakas M; Hansen GL; Gaudernack G; Aamdal S
Clin Cancer Res; 2011 Nov; 17(21):6847-57. PubMed ID: 21918169
[TBL] [Abstract][Full Text] [Related]
4. Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001.
Vetsika EK; Konsolakis G; Aggouraki D; Kotsakis A; Papadimitraki E; Christou S; Menez-Jamet J; Kosmatopoulos K; Georgoulias V; Mavroudis D
Cancer Immunol Immunother; 2012 Feb; 61(2):157-168. PubMed ID: 21858533
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study.
Kotsakis A; Vetsika EK; Christou S; Hatzidaki D; Vardakis N; Aggouraki D; Konsolakis G; Georgoulias V; Christophyllakis Ch; Cordopatis P; Kosmatopoulos K; Mavroudis D
Ann Oncol; 2012 Feb; 23(2):442-9. PubMed ID: 21873272
[TBL] [Abstract][Full Text] [Related]
6. Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patients.
Vetsika EK; Papadimitraki E; Aggouraki D; Konsolakis G; Mela ME; Kotsakis A; Christou S; Patramani S; Alefantinou M; Kaskara A; Christophyllakis C; Kosmatopoulos K; Georgoulias V; Mavroudis D
J Immunother; 2011; 34(9):641-50. PubMed ID: 21989412
[TBL] [Abstract][Full Text] [Related]
7. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
8. Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial.
Gridelli C; Ciuleanu T; Domine M; Szczesna A; Bover I; Cobo M; Kentepozidis N; Zarogoulidis K; Kalofonos C; Kazarnowisz A; Korozan M; de Las Penas R; Majem M; Chella A; Griesinger F; Bournakis E; Sadjadian P; Kotsakis A; Chinet T; Syrigos KN; Correale P; Gallou C; Jamet JM; Vetsika EK; Kosmatopoulos K; Georgoulias V;
Br J Cancer; 2020 May; 122(10):1461-1466. PubMed ID: 32210365
[TBL] [Abstract][Full Text] [Related]
9. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.
Iversen TZ; Engell-Noerregaard L; Ellebaek E; Andersen R; Larsen SK; Bjoern J; Zeyher C; Gouttefangeas C; Thomsen BM; Holm B; Thor Straten P; Mellemgaard A; Andersen MH; Svane IM
Clin Cancer Res; 2014 Jan; 20(1):221-32. PubMed ID: 24218513
[TBL] [Abstract][Full Text] [Related]
10. Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens.
Yamada T; Terazaki Y; Sakamoto S; Yoshiyama K; Matsueda S; Komatsu N; Waki K; Yamada A; Kawahara A; Kage M; Sugawara S; Yamashita Y; Sasada T; Takamori S; Itoh K
Int J Oncol; 2015 Jan; 46(1):55-62. PubMed ID: 25310280
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.
Raez LE; Cassileth PA; Schlesselman JJ; Sridhar K; Padmanabhan S; Fisher EZ; Baldie PA; Podack ER
J Clin Oncol; 2004 Jul; 22(14):2800-7. PubMed ID: 15254047
[TBL] [Abstract][Full Text] [Related]
12. Personalized peptide vaccination in patients with refractory non-small cell lung cancer.
Yoshiyama K; Terazaki Y; Matsueda S; Shichijo S; Noguchi M; Yamada A; Mine T; Ioji T; Itoh K; Shirouzu K; Sasada T; Takamori S
Int J Oncol; 2012 May; 40(5):1492-500. PubMed ID: 22307435
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
Brunsvig PF; Guren TK; Nyakas M; Steinfeldt-Reisse CH; Rasch W; Kyte JA; Juul HV; Aamdal S; Gaudernack G; Inderberg EM
Front Immunol; 2020; 11():572172. PubMed ID: 33324397
[TBL] [Abstract][Full Text] [Related]
14. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
Nemunaitis J; Dillman RO; Schwarzenberger PO; Senzer N; Cunningham C; Cutler J; Tong A; Kumar P; Pappen B; Hamilton C; DeVol E; Maples PB; Liu L; Chamberlin T; Shawler DL; Fakhrai H
J Clin Oncol; 2006 Oct; 24(29):4721-30. PubMed ID: 16966690
[TBL] [Abstract][Full Text] [Related]
16. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
Barve M; Bender J; Senzer N; Cunningham C; Greco FA; McCune D; Steis R; Khong H; Richards D; Stephenson J; Ganesa P; Nemunaitis J; Ishioka G; Pappen B; Nemunaitis M; Morse M; Mills B; Maples PB; Sherman J; Nemunaitis JJ
J Clin Oncol; 2008 Sep; 26(27):4418-25. PubMed ID: 18802154
[TBL] [Abstract][Full Text] [Related]
17. Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma.
Raez LE; Cassileth PA; Schlesselman JJ; Padmanabhan S; Fisher EZ; Baldie PA; Sridhar K; Podack ER
Cancer Gene Ther; 2003 Nov; 10(11):850-8. PubMed ID: 14605671
[TBL] [Abstract][Full Text] [Related]
18. Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination.
Hansen GL; Gaudernack G; Brunsvig PF; Cvancarova M; Kyte JA
Cancer Immunol Immunother; 2015 Dec; 64(12):1609-21. PubMed ID: 26498005
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.
Patil R; Clifton GT; Holmes JP; Amin A; Carmichael MG; Gates JD; Benavides LH; Hueman MT; Ponniah S; Peoples GE
J Am Coll Surg; 2010 Feb; 210(2):140-7. PubMed ID: 20113933
[TBL] [Abstract][Full Text] [Related]
20. Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report.
Kjeldsen JW; Iversen TZ; Engell-Noerregaard L; Mellemgaard A; Andersen MH; Svane IM
Front Immunol; 2018; 9():2145. PubMed ID: 30283461
[No Abstract] [Full Text] [Related]
[Next] [New Search]
